Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease by Klusa, Vija Z. et al.
Int. J. Mol. Sci. 2010, 11, 4465-4487; doi:10.3390/ijms11114465 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
Neuroprotective Properties of Mildronate, a Small Molecule, in 
a Rat Model of Parkinson’s Disease 
Vija Z. Klusa 
1,*, Sergejs Isajevs 
2, Darja Svirina 
2, Jolanta Pupure 
1, Ulrika Beitnere 
1,  
Juris Rumaks 
1, Simons Svirskis 
1, Baiba Jansone 
1, Zane Dzirkale 
1, Ruta Muceniece 
1,  
Ivars Kalvinsh 
3 and Harry V. Vinters 
4 
1  Department of Pharmacology, Faculty of Medicine, University of Latvia, Riga, Latvia 
2  Department of Pathology, Faculty of Medicine, University of Latvia, Riga, Latvia 
3  Latvian Institute of Organic Synthesis, Riga, Latvia 
4  Department of Pathology and Laboratory of Medicine and Neurology, University of California Los 
Angeles, Los Angeles, CA, USA 
*  Author to whom correspondence should be addressed; E-Mail: vijaklus@latnet.lv;  
Tel.: +371-292-762-63; Fax: +371-673-663-06. 
Received: 20 September 2010; in revised form: 22 October 2010 / Accepted: 27 October 2010 / 
Published: 9 November 2010 
 
Abstract:  Previously,  we  have  found  that  mildronate  [3-(2,2,2-trimethylhydrazinium) 
propionate dihydrate], a small molecule with charged nitrogen and oxygen atoms, protects 
mitochondrial  metabolism  that  is  altered  by  inhibitors  of  complex  I  and  has 
neuroprotective effects in an azidothymidine-neurotoxicity mouse model. In the present 
study, we investigated the effects of mildronate in a rat model of Parkinson’s disease (PD) 
that  was  generated  via  a  unilateral  intrastriatal  injection  of  the  neurotoxin  
6-hydroxydopamine (6-OHDA). We assessed the expression of cell biomarkers that are 
involved  in  signaling  cascades  and  provide  neural  and  glial  integration:  the  neuronal 
marker  TH  (tyrosine  hydroxylase);  ubiquitin  (a  regulatory  peptide  involved  in  the 
ubiquitin-proteasome degradation system); Notch-3 (a marker of progenitor cells); IBA-1 
(a  marker  of  microglial  cells);  glial  fibrillary  acidic  protein,  GFAP  (a  marker  of 
astrocytes); and inducible nitric oxide synthase, iNOS (a marker of inflammation). The 
data show that in the 6-OHDA-lesioned striatum, mildronate completely prevented the loss 
of TH, stimulated Notch-3 expression and decreased the expression of ubiquitin, GFAP 
and  iNOS.  These  results  provide  evidence  for  the  ability  of  mildronate  to  control  the 
expression  of  an  array  of  cellular  proteins  and,  thus,  impart  multi-faceted  homeostatic 
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mechanisms in neurons and glial cells in a rat model of PD. We suggest that the use of 
mildronate provides a protective effect during the early stages of PD that can delay or halt 
the progression of this neurodegenerative disease. 
Keywords:  Parkinson’s  disease;  6-OHDA  model;  neuroimmunological  biomarkers; 
mildronate; small molecule 
 
1. Introduction  
Parkinson’s  disease  (PD)  is  clearly  defined  as  a  neurodegenerative  disorder  that  involves 
multifactorial mechanisms, such as mitochondrial dysfunction, neuronal apoptosis, neuroinflammation 
and  microglial  activation,  which  leads  to  the  progressive  loss  of  dopamine-producing  cells  in  the 
nigro-striatal system [1,2]. Unfortunately, the conventional therapy for PD focuses primarily on the 
consequences of this neuronal loss: the stimulation of degenerating dopamine cells [3]. Therefore, 
novel pharmacotherapeutic strategies are being developed that focus on cellular targets to prevent or 
delay dopamine-induced cell death at much earlier stages of neurodegeneration. These approaches may 
reveal novel strategies for the treatment of PD.  
Mitochondria  can  be  considered  one  of  these  novel  drug  targets.  There  are  several  arguments 
supporting the view that genetic defects in mitochondria play a prevalent role in the pathogenesis of 
PD [4–6]. Defects in complex I are considered a central and early cause of PD [4] because a deficiency 
in  complex  I  activity  initiates  further  respiratory  chain  dysfunctions  that  involve 
mitochondria-dependent apoptotic cascades and result in cell death [7].  
Therefore, the protection of mitochondria, even their repair mechanisms at the level of complex I, 
may be a key strategy in limiting mitochondrial damage and ensuring cellular integrity [8]. At present, 
drugs that provide such effect have not been found.  
A  more  complicated  problem  is  the  determination  of  ways  to  control  the  development  of 
pathological changes in protein conformations that are associated with PD. Mutations in the genes that 
encode  a  series  of  proteins,  particularly  α-synuclein  (SNCA),  parkin,  DJ-1,  PINK1,  LRRK2  and 
HTR2A, lead to the formation of misfolded protein conformations that are harmful to cells [1,2]. The 
aggregation of α-synuclein in Lewy bodies plays a crucial role in cell death because such aggregates 
activate pro-inflammatory molecules and switch on the neuroinflammatory and apoptotic events that 
lead to cell death. Recent evidence suggests that misfolded proteins and their aggregates are closely 
related to the activities of endogenous or molecular chaperones, which are intracellular molecules that 
are capable of unfolding proteins [9]. Among these chaperones, the heat shock protein (HSP) family is 
the most commonly studied group.  
Decreasing  levels  of  HSP  and  α-synuclein  aggregation  in  Lewy  bodies  coincide  with  the 
progression  of  PD  [10].  Experimental  data  show  that  HSP70  may  inhibit  α-synuclein  fibril 
formation [11] and possess anti-apoptotic activity [10].  
Designing chemical or pharmacological chaperones (pharmacoperons) that can unfold misfolded 
proteins  in  a  similar  manner  to  endogenous  molecules  is  an  attractive  approach  for  future  PD 
therapies [12].  Numerous  molecules  have  been  shown  to  possess  the  properties  of  chemical Int. J. Mol. Sci. 2010, 11                       
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chaperones, such as glycerol, diltiazem, vinblastine, trimethylamine N-oxide, rifampicin, flavonoids 
and glycine betaine [13–17]. 
A  very  important  consequence  of  a  build-up  and  aggregation  of  misfolded  proteins  is  the 
impairment of the ubiquitin-proteasome degradation system (UPS) [10]. Normally, proteins that are 
conjugated to ubiquitin are targeted to the UPS where they undergo proteolytic degradation [18]. The 
ubiquitin/proteasome  pathway  is  the  major  proteolytic  quality  control  system  in  cells,  and 
ubiquitin-enriched Lewy bodies in dopaminergic neurons are a hallmark of PD [19]. A high level of 
ubiquitin and ubiquitinated proteins (i.e., ubiquitin that is covalently attached to target proteins) in 
Lewy  bodies  indicates  that  protein  degradation  by  proteasomes  is  impaired  [20].  Therefore, 
ubiquitination pathways may play a central role in the pathogenesis of PD [18], and the regulation of 
the level of ubiquitin may serve as another drug target.  
Others studies emphasize glial cells as a target for the treatment of PD. Microglial activation plays 
an important role in the early stages (before dopaminergic cell death) of PD pathogenesis [21]. This 
activation  triggers  the  onset  of  a  molecular  cascade  that  leads  to  the  progressive  degeneration  of 
cells [22].  Therefore,  the  blockade  of  microglial  activation  might  be  a  target  for  therapeutic 
intervention in PD [23]. Moreover, a new concept of glia as a stem cell element in the brain has been 
recently proposed [24]. Furthermore, astrocytes are involved in the formation of synapses and in the 
modulation of synaptic functions via a bidirectional communication with neurons [25]. Brain damage 
caused  by  stroke,  degeneration  or  demyelination  may  elicit  reactive  astrogliosis,  which  has  been 
suggested  to  impede  neuronal  survival  [23].  Conversely,  activated  astrocytes  may  promote 
neurogenesis by producing energy-producing compounds and neurotrophins [26,27]. Neurotrophins, 
such as glial cell line-derived neurotrophic factor (GDNF) [28] and mesencephalic astrocyte-derived 
neurotrophic factor (MANF) [29], have been proposed to promote the survival and differentiation of 
dopamine  neurons.  Nevertheless,  their  clinical  use  is  limited  by  their  large  molecular  size 
and antigenicity.  
In this context, the idea of adult neurogenesis as a potential tool for the restoration of lost dopamine 
neurons might open new vistas for the development of novel therapeutics in PD [30]. Although neural 
or  fetal  stem  cell  transplantation  has  been  used  previously  to  replace  damaged  neurons  [31],  the 
stimulation of endogenous progenitor cells is an exciting alternative [32]. In PD brain structures, a 
decrease in progenitor cell proliferation has been demonstrated [33]. In a 6-OHDA-lesioned PD model 
in rats, an increase in progenitor cell proliferation in nigro-striatal structures has been noted [32]. The 
search for drugs that are capable of regulating progenitor cell proliferation in the treatment of PD is a 
very  new  and  critical  issue.  Guanosine  was  recently  shown  to  induce  the  proliferation  of  neural 
progenitor stem cells in the adult SN and subventricular zone in a proteasome inhibitor-induced PD 
model in rats [34].  
Small  molecules  that  are  capable  of  altering  the  structure  of  proteins  may  be  optimal 
pharmacophores (e.g., positively charged moieties) and serve as privileged molecules that can bind 
easily to the negatively charged amino acids of cellular proteins and target protein-protein interactions. 
Therefore, these small molecules may affect protein conformations and act as multivalent regulators of 
intracellular processes.  Int. J. Mol. Sci. 2010, 11                       
 
4468 
Small  molecules  have  been  suggested  to  function  as  multi-protein  co-activators  of  gene 
transcription [35]. Therefore, small molecules may demonstrate a beneficial protective effect in PD by 
slowing or halting the progression of the disease during its early stages.  
We  propose  that  mildronate  (Figure  1),  a  representative  of  the  aza-butyrobetaine  class  of 
compounds, partially meets the requirements for small molecules. Mildronate possesses a quaternary 
nitrogen and a negatively charged oxygen. These charged moieties might change the conformation of 
mildronate from a linear to a cyclic one via intramolecular electrostatic interactions. Cyclic mildronate 
is a neutral molecule, which allows it to penetrate the brain. Recently, an HPLC method was used to 
detect mildronate at a concentration of 102 ±  22 nmol/g in brain tissue after a 21 day intraperitoneal 
administration  of  100  mg/kg  [36].  In  an  azidothymidine  neurotoxicity  model  in  rats,  mildronate 
suppressed the neuroinflammatory and apoptotic processes in brain tissue by protecting the abnormal 
expression of cytochrome oxidase c, caspase-3, iNOS, cellular apoptosis susceptibility (CAS) protein 
and glial fibrillary acidic protein (GFAP) [37]. In addition, data from our previous studies have shown 
that  mildronate  plays  a  protective  role  against  mitochondrial  complex  I  damage  caused  by 
mitochondria-compromising substances, such as rotenone and the anti-HIV drug azidothymidine [38]. 
The present study investigated the effects of mildronate in a 6-OHDA rat model of PD by assessing 
cellular biomarkers that are involved in signaling cascades and that are crucial for neural and glial 
integration: the neuronal marker TH (tyrosine hydroxylase); ubiquitin (a regulatory peptide involved in 
the ubiquitin-proteasome degradation system); Notch-3 (a marker of progenitor cells); IBA-1 (ionised 
calcium-binding adaptor molecule 1, a marker  of microglia);  glial fibrillary  acidic protein, GFAP 
(a marker of astrocytes); inducible nitric oxide synthase, iNOS (a marker of inflammation).  
Figure 1. The structure of mildronate (A) and models of its linear (B) and cyclic (C) 
conformations. Charged atoms in the mildronate structure: nitrogen in blue; oxygen in red; 
lipophilic hydrogen in gray. When mildronate forms a cyclic conformation, it can easily 
penetrate the brain and cells.  
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2. Results 
2.1. Effects on Apomorphine-Induced Rotations  
In  saline  control  and  mildronate-treated  (50  or  100  mg/kg)  rats  without  6-OHDA  lesions, 
apomorphine did not induce rotations (data not shown). Significant apomorphine-induced turning rates 
on days 14, 21 and 28 after 6-OHDA injection were observed, particularly on day 21 (Figure 2). 
Mildronate  (50 mg/kg)  in  combination  with  6-OHDA  significantly  reduced  apomorphine-induced 
rotations on day 21 after surgery (78.8 ±  13.5 vs. 147.0 ±  20.9, p = 0.003); on day 28, a tendency 
toward an increased rotation was observed. A mildronate dose of 100 mg/kg showed an effect that was 
similar to that caused by 50 mg/kg (data not shown).  
Figure 2. Number of apomorphine-induced contralateral rotations in rats (n = 8 per group). 
The number of apomorphine-induced contralateral rotations were documented over 30 min 
on days 14, 21 and 28 after a unilateral intrastriatal injection of 6-OHDA (20 μg) into the 
right  striatum.  Apomorphine was  administered subcutaneously  at  a dose of 0.2 mg/kg. 
Pretreatment with saline (SAL, 1 mL/kg) or mildronate at a dose of 50 mg/kg (M50) was 
performed via intraperitoneal administration for two weeks before the administration of  
6-OHDA (SAL + 6-OHDA and M50 + 6-OHDA), at ** p < 0.01, M50 + 6-OHDA vs.  
SAL + 6-OHDA group, day 21, unpaired t-test. 
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2.2. Tyrosine Hydroxylase (TH) Expression in Striatum and Substantia Nigra  
The  expression  of  TH  in  the  striatum  was  assessed  by  counting  the  number  of  nerve  endings 
(fibers), and the number of neurons was counted in the SN (Figure 3; photomicrograph in Figure 4). 
The data demonstrated that 6-OHDA lesions caused a dramatic (five-fold) decrease in TH-positive 
nerve endings in the lesioned striatum in comparison to the control group (5 ±  2 vs. 21 ±  10 nerve 
endings/per mm
2, p = 0.03). Mildronate per se at the doses of 50 and 100 mg/kg did not influence the 
density of TH-positive nerve endings. However, the administration of mildronate completely protected 
against the 6-OHDA-induced decrease in the density of nerve endings (50 mg/kg, 25 ±  4 vs. 5 ±  2 Int. J. Mol. Sci. 2010, 11                       
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nerve  endings/mm
2,  100  mg/kg,  31  ±   3  vs.  5  ±   2  nerve  fibers/mm
2,  p  =  0.001  and  p  =  0.0002, 
respectively; Figure 3A).  
In the SN, 6-OHDA caused an approximately 2.5-fold decrease in TH levels in comparison to the 
control group (44 ±  14 vs. 95 ±  30 neurons/mm
2, p = 0.01). Mildronate at a dose of 100 mg/kg 
protected against the effect of 6-OHDA in this brain structure (78 ±  16 vs. 44 ±  14 neurons/mm
2,  
p = 0.04; Figure 3B). 
Figure  3.  The  number  of  tyrosine  hydroxylase  (TH)-positive  nerve  endings  in  the 
6-OHDA-lesioned  striatum  (A)  and  of  TH-positive  neurons  in  the  substantia  nigra 
(B). Immunohistochemical examination of rat tissue using a TH antibody. Saline (SAL, 
1 mL/kg) or mildronate at doses of 50 or 100 mg/kg (M50 and M100, respectively) were 
administered intraperitoneally for two weeks prior to an injection of 6-OHDA (20 µg) or 
artificial  cerebrospinal  fluid  (aCSF);  6-OHDA  injection  in  mildronate-treated  rats:  
M50  +  6-OHDA  and  M100  +  6-OHDA.  Striatum:  *  p  =  0.04,  SAL  +  6-OHDA  vs. 
SAL + aCSF;  **  p  =  0.001,  M50  +  6-OHDA  vs.  SAL  +  6-OHDA;  ***  p  =  0.0002,  
M100  +  6-OHDA  vs.  SAL  +  6-OHDA;  S.  nigra:  *  p  =  0.04,  SAL  +  6-OHDA  vs.  
Sal + aCSF; ** p = 0.04, M100 + 6-OHDA vs. SAL + 6-OHDA; unpaired t-test. Number 
of animals per group (n = 8). 
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Figure 4. Photomicrograph of tyrosine hydroxylase (TH)-positive neurons in the substantia 
nigra  and  TH-positive  nerve  endings  in  a  6-OHDA-lesioned  striatum. 
Immunohistochemical staining, magnification ×  400. Internal scale bar = 25 μm. S. nigra: 
(A) Saline control (SAL + aCSF); (B) SAL + 6-OHDA; the arrow indicates positively 
stained  neurons.  (C)  Striatum:  saline  control  (SAL  +  aCSF);  (D)  Mildronate  at  
50  mg/kg  +  artificial  cerebrospinal  fluid  (M50  +  aCSF);  (E)  SAL  +  6-OHDA;  
(F) M50 + 6-OHDA; the arrows indicate TH-positive nerve endings. 
 
 
 
2.3. The Number of Cells with Intracellular Ubiquitin-Positive Inclusions in Striatum and Substantia 
Nigra  
In the saline group, a weak, diffuse ubiquitin positive staining was observed. However, cells that 
contained  ubiquitin-positive  inclusions  were  rare  (Figure  5,  photomicrograph  in  Figure  6).  In  the  
6-OHDA group, we observed a three-fold increase in the number of cells with intracellular ubiquitin-
positive inclusions in the striatum in comparison to the control (35 ±  4 vs. 12 ±  2 cells/mm
2, p = 0.001, 
Figure 5A). Mildronate per se at a dose of 50 mg/kg did not significantly influence the number of cells Int. J. Mol. Sci. 2010, 11                       
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that contained ubiquitin-positive inclusions. However, a dose of 100 mg/kg tended to decrease the 
number of cells that contained these inclusions. Mildronate at both doses, particularly at 100 mg/kg  
co-administered with 6-OHDA, significantly decreased the 6-OHDA-induced increase in the number 
of cells with intracellular ubiquitin-positive inclusions (11 ±  3 vs. 35 ±  4 cells/mm
2, p = 0.001, and  
6 ±  2 vs. 35 ±  4 cells/mm
2, p = 0.0002). 
In  the  rat  SN  in  the  6-OHDA  experimental  group,  the  number  of  neurons  that  contained 
ubiquitin-positive  inclusions  was  significantly  increased  in  comparison  to  the  control  (21  ±   2  vs. 
9 ±  3 cells/mm
2, p = 0.01). Mildronate per se at doses of 50 mg/kg and 100 mg/kg did not influence 
the number of neurons that contained ubiquitin-positive inclusions. However, the administration of 
mildronate  significantly  decreased  the  6-OHDA-induced  increase  in  the  number  of  cells  with 
intracellular ubiquitin-positive inclusions (8 ±  2 vs. 21 ±  2 cells/mm
2, p = 0.003, and 10 ±  3  vs. 
21 ±  2 cells/mm
2, p = 0.01; Figure 5B). 
Figure  5.  The  number  of  cells  that  contained  ubiquitin-positive  inclusions  in  the  
6-OHDA-lesioned  striatum  (A)  and  substantia  nigra  (B).  Immunohistochemical 
examination  of  rat  tissue  using  a  ubiquitin  antibody.  Saline  at  1  mL/kg  (control)  and 
mildronate  at  doses  of  50  and  100  mg/kg  were  administered  intraperitoneally  for  two 
weeks prior to the injection of 6-OHDA (20 µg) or artificial cerebrospinal fluid (aCSF);  
6-OHDA injection in  mildronate-treated rats: M50 + 6-OHDA and M100 + 6-OHDA. 
Striatum: *
 p = 0.001, SAL + 6-OHDA vs. SAL + aCSF; ** p = 0.001, M50 + 6-OHDA vs. 
SAL + 6-OHDA; S. nigra: *** p = 0.01, M100 + 6-OHDA vs. SAL + 6-OHDA; unpaired  
t-test. Number of animals per group (n = 8). 
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Figure 6. Photomicrograph showing cells containing ubiquitin-positive inclusions in the 
rat  6-OHDA-lesioned  striatum.  Immunohistochemical  staining,  magnification  ×   400. 
Internal scale bar = 25 µm. (A) Saline control (SAL + aCSF); (B) mildronate at 50 mg/kg 
(M50 + aCSF); (C) 6-OHDA (SAL + 6-OHDA); (D) M50 + 6-OHDA; Arrows indicate 
cells containing ubiquitin-positive inclusions in the 6-OHDA group. 
 
2.4. Notch-3 Expression in Striatum and Substantia Nigra  
The administration of 6-OHDA decreased the number of Notch-3-positive cells in the rat striatum 
in comparison to the control group (3 ±  1 vs. 6 ±  1 cells/mm
2, p = 0.04; Figures 7A and 8). Mildronate 
at doses of 50 mg/kg and 100 mg/kg tended to increase and decrease the number of Notch-3-positive 
cells, respectively. Mildronate (50 mg/kg) co-administered with 6-OHDA increased the number of 
Notch-3-positive cells in comparison to the 6-OHDA group (9 ±  3 vs. 3 ±  1 cells/mm
2, p = 0.045). The 
100 mg/kg dose of mildronate tended to increase the number of Notch-3-positive cells compared to  
6-OHDA group. 
In the rat SN, 6-OHDA decreased the number of Notch-3-positive cells in comparison to the control 
group (5 ±  1 vs. 11 ±  2 cells/mm
2, p = 0.05). Mildronate at 50 mg/kg, but not at 100 mg/kg, tended to 
increase  the  number  of  Notch-3-positive  cells.  Mildronate  at  50  mg/kg,  but  not  at  100  mg/kg, 
co-administered with 6-OHDA increased the number of Notch-3-positive cells in comparison to the 
6-OHDA group (11 ±  2 vs. 5 ±  1 cells/mm
2, p = 0.03; Figures 7B and 8). Int. J. Mol. Sci. 2010, 11                       
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Figure 7. The number of Notch-3-positive cells in the 6-OHDA-lesioned striatum (A) and 
substantia  nigra  (B).  Immunohistochemical  examination  of  rat  tissue  using  a  Notch-3 
antibody.  Saline  at  1  mL/kg,  control  (SAL),  and  mildronate  at  50  mg/kg  (M50)  and 
100 mg/kg (M100) were administered intraperitoneally for two weeks prior to the injection 
of  6-OHDA  or  artificial  cerebrospinal  fluid  (aCSF);  6-OHDA  injection  in 
mildronate-treated rats: M50 + 6-OHDA and M100 + 6-OHDA. Striatum:  *
 p =  0.03, 
SAL + 6-OHDA  vs.  SAL  +  aCSF;  •p  =  0.04,  M50  +  6-OHDA  vs.  SAL  +  6-OHDA 
S. nigra: * p = 0.049, SAL + 6-OHDA vs. SAL + aCSF; •p = 0.03, M50 + 6-OHDA vs. 
SAL + 6-OHDA; unpaired t-test. Number of animals per group (n = 8). 
   
Figure  8.  Photomicrograph  of  Notch-3-positive  cells  in  the  striatum. 
Immunohistochemical  staining,  magnification  ×   200.  Internal  scale  bars  =  50  μm. 
(A) Saline;  (B)  mildronate  at  50  mg/kg;  (C)  6-OHDA;  (D)  M50  +  6-OHDA.  The 
administration  of  6-OHDA  decreased  the  number  of  Notch-3-positive  cells  in  the  rat 
striatum, but the co-administration of mildronate at 50 mg/kg and 6-OHDA increased the 
number of Notch-3-positive cells to values similar to those observed in controls. Arrows 
indicate positively stained cells. 
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2.5. GFAP Expression in Striatum and Substantia Nigra  
Figure 9A shows that in the 6-OHDA-lesioned striatum, a four-fold increase in the number of 
GFAP-positive  glial  cells  was  observed  in  comparison  to  the  control  group  (42  ±   6  vs. 
11 ±  3 cells/mm
2, p = 0.001). Mildronate alone at doses of 50 and 100 mg/kg did not significantly 
influence GFAP expression. However, in the mildronate-treated rats (50 mg/kg), a two-fold decrease 
in 6-OHDA-induced GFAP overexpression was observed (20 ±  4 vs. 42 ±  6 cells/mm
2, p = 0.01). 
The administration of 6-OHDA also caused GFAP overexpression in the SN in comparison to the 
control group (35 ±  5 vs. 11 ±  3 cells/mm
2, p = 0.002; Figure 9B). The co-administration of mildronate 
at 50 mg/kg and 6-OHDA showed a tendency to decrease the number of GFAP-positive glial cells. 
Mildronate at 100 mg/kg was not tested in this study. 
Figure 10A, B shows the immunohistochemical staining for GFAP-positive astrocytes. 
Figure 9. (A) The number of GFAP-positive astrocytes in the 6-OHDA-lesioned striatum; 
and (B) substantia nigra. Immunohistochemical examination of rat tissue using a GFAP 
antibody.  Saline  (SAL,  1  mL/kg)  and  mildronate  at  50  mg/kg  (M50)  and  100  mg/kg 
(M100) were administered intraperitoneally two weeks prior to the injection of 6-OHDA or 
artificial  cerebrospinal  fluid  (aCSF);  6-OHDA  injection  in  mildronate-treated  rats:  
M50  +  6-OHDA  and  M100  +  6-OHDA.  Striatum:  *  p  =  0.001,  SAL  +  6-OHDA  vs.  
SAL + aCSF; ** p = 0.01, M50 + 6-OHDA vs. SAL + 6-OHDA; S. nigra: * p = 0.002,  
SAL + 6-OHDA vs. SAL + aCSF; unpaired t-test. Number of animals per group (n = 8). 
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Figure  10.  Photomicrograph  of  GFAP,  iNOS  positive  cells  in  the  6-OHDA-lesioned 
striatum  and  IBA-1  positive  cells  in  S.nigra.  Immunohistochemical  staining, 
magnification ×  400. Internal scale bar = 25 μm. (A) GFAP: SAL + aCSF; (B) GFAP: 
SAL + 6-OHDA;  (C)  iNOS:  SAL  +  aCSF;  (D)  iNOS:  SAL  +  6-OHDA;  (E) IBA-1:  
SAL + aCSF; (F) IBA-1: SAL + 6-OHDA. Arrows indicate positively stained cells. 
 
2.6. IBA-1-Expression in Striatum and Substantia Nigra  
An increase in the number of IBA-1-positive cells was found in the 6-OHDA-lesioned striatum in 
comparison to the control group (23 ±  3 vs. 12 ±  2 cells/mm
2, p = 0.03; Figure 11A). Mildronate at  
50 and 100 mg/kg did not significantly influence IBA-1 expression in comparison to the control group. 
The co-administration of mildronate at  50 mg/kg and 6-OHDA tended to  increase the number of 
IBA-1-positive cells. However, a dose of 100 mg/kg mildronate tended to decrease the number of 
IBA-1-positive cells. 
The administration of 6-OHDA significantly increased the number of IBA-1-positive cells in the 
SN in comparison to the control group (32 ±  8 vs. 11 ±  2 cells/mm
2, p = 0.04; Figure 11). Mildronate 
per se at doses of 50 and 100 mg/kg did not significantly influence the expression of IBA-1, but the 
co-administration  of  mildronate  and  6-OHDA  showed  a  tendency  to  decrease  the  number  of 
IBA-1-positive cells (18 ±  2 vs. 32 ±  8, p = 0.14; and 17 ±  2 vs. 32 ±  8, p = 0.15, respectively). 
Figure 10E, F shows the immunohistochemical staining for IBA-1-positive microglial cells. Int. J. Mol. Sci. 2010, 11                       
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Figure 11. The number of IBA-1-positive cells in the 6-OHDA-lesioned striatum (A) and 
substantia  nigra  (B).  Immunohistochemical  examination  of  rat  tissue  using  an  IBA-1 
antibody. Saline (SAL, 1 mL/kg) and mildronate at doses of 50 mg/kg and 100 mg/kg 
(M50 and M100, respectively) were administered intraperitoneally two weeks before the 
injection  of  6-OHDA  or  artificial  cerebrospinal  fluid  (aCSF);  6-OHDA  injection  in 
mildronate-treated  rats:  M50  +  6-OHDA  and  M100  +  6-OHDA;  striatum:  *
  p  =  0.03, 
SAL + 6-OHDA vs. SAL + aCSF; s. nigra: * p = 0.04, SAL + 6-OHDA vs. SAL + aCSF; 
unpaired t-test. Number of animals per group (n = 8). 
 
2.7. iNOS Expression in Striatum and Substantia Nigra  
Figure 12. The number of iNOS-positive cells in the 6-OHDA-lesioned striatum (A) and 
substantia  nigra  (B).  Immunohistochemical  examination  of  rat  tissue  using  an  iNOS 
antibody. Saline (SAL, 1 mL/kg) and mildronate at doses of 50 mg/kg and 100 mg/kg 
(M50 and M100, respectively) were administered intraperitoneally two weeks prior to the 
injection  of  6-OHDA  or  artificial  cerebrospinal  fluid  (aCSF);  6-OHDA  injection  in 
mildronate-treated  rats:  M50  +  6-OHDA  and  M100 + 6-OHDA;  striatum:  *
  p  =  0.02,  
SAL + 6-OHDA vs. SAL + aCSF; s. nigra: *
 p = 0.007, SAL + 6-OHDA vs. SAL + aCSF; 
** p = 0.045, M50 + 6-OHDA vs. SAL + 6-OHDA; *** p = 0.04, M100 + 6-OHDA vs. 
SAL + 6-OHDA; unpaired t-test. Number of animals per group (n = 8). 
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The administration of 6-OHDA caused a considerable increase in iNOS expression in the lesioned 
striatum  and  SN  (Figure  12A,  B).  Mildronate  alone  did  not  influence  iNOS  expression.  The  
co-administration  of  mildronate  at  a  dose  of  50  mg/kg  and  6-OHDA  significantly  decreased  the 
number of iNOS-positive cells in the SN (Figure 12B).  
Figure 10C, D show the immunohistochemical staining for iNOS-positive cells. 
3. Discussion 
Recent  new  data  demonstrate  that  macroglial  and  microglial  cells  contribute  considerably  to 
homeostasis in the brain [25]. Therefore, novel therapeutic strategies for the treatment of PD can be 
rationally focused on both neuronal and glial processes. Mitochondria, which play a critical role in the 
aetiology of PD [39], can be considered one of the most essential targets that are common to both 
neurons and glial cells. The oxidation rates of various substrates and the acceptor control ratios do not 
differ appreciably between neuronal and glial cell mitochondria [40]. In this context, mitochondria are 
vulnerable to the effects of 6-OHDA-induced cell death [41]. Moreover, 6-OHDA has been proposed 
to be a putative endogenous neurotoxic factor in the pathogenesis of PD because it can be generated 
from dopamine via non-enzymatic hydroxylation processes in the presence of Fe
2+ and H2O2 [42]. 
We suggest that a small molecule, mildronate, might function as a suitable “interface molecule” 
between neuronal and glial systems and correct the imbalances that are present in the rat model of PD. 
This  assumption  was  based  on  our  previous  findings  that  demonstrated  the  protective  effects  of 
mildronate  at  the  level  of  the  mitochondrial  respiratory  chain  complex  I  [38]  and  the  ability  of 
mildronate  to  exert  anti-inflammatory  and  anti-apoptotic  effects  in  a  rat  model  of  neurotoxicity 
generated with the mitochondria-compromising drug azidothymidine [37]. In the present study, we 
assessed numerous markers of impaired neuronal and glial cell functions in the nigro-striatal system. 
In  our  study  the  rotations  behavior  test  showed  that  both  doses  of  mildronate  decreased  the 
apomorphine rotations in 6-OHDA-treated rats, particularly on day 21, which indicated that mildronate 
attenuated behavioral disturbances in a PD model.  
An immunohistochemical examination of brain tissue ex vivo demonstrated that 6-OHDA-induced 
lesions were associated with a massive loss of neuronal dopamine, a dramatic (five-fold) decrease in 
the  number  of  TH-positive  nerve  endings  in  the  lesioned  striatum  and  an  approximately  2.5-fold 
decrease  in  the  number  of  TH-positive  neurons  in  the  SN  in  comparison  to  the  control  group 
(saline + aCSF). The administration of mildronate at a dose of 50 mg/kg provided complete protection 
against the 6-OHDA-induced degeneration of TH-positive nerve endings in the lesioned striatum. In 
addition, mildronate at 100 mg/kg protected against the loss of TH-positive dopaminergic neurons in 
the SN. 
Our results are consistent with previous findings demonstrating that 6-OHDA decreased both the 
number of TH-positive nerve endings in the striatum and the number of TH dopaminergic neurons in 
the SN [23]. Therefore, our data demonstrate the neuroprotective properties of mildronate against a 
6-OHDA-induced loss of TH expression. These findings raise the following question: what are the 
crucial mechanisms responsible for this protective action of mildronate?  
Our  results  demonstrated  the  ability  of  mildronate  to  completely  prevent  (to  control  level)  the 
6-OHDA-induced formation of ubiquitin intracellular inclusions in both the rat striatum and SN. The Int. J. Mol. Sci. 2010, 11                       
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increased level of unconjugated ubiquitin and the formation of intracellular ubiquitin inclusions in the 
6-OHDA dopamine-depleted striatum observed in the present study are consistent with the findings 
presented in  the literature  [43]. The effect  of mildronate leads  us  to  suggest  that it is  capable  of 
regulating the ubiquitin proteasome pathway, probably by activating the proteasome and/or enhancing 
ubiquitination and thereby promoting protein degradation. An explanation of this effect may be the 
ability of mildronate to protect cells at the level of the mitochondria [38] because disturbances in 
ubiquitin  production  depend  largely  on  oxidative  stress-induced  impairments  in  glucolysis  and 
mitochondrial respiration [44]. The central role of the ubiquitin-proteasome system in regulating the 
degradation  of  cellular  proteins  under  different  physiological  conditions  has  been  increasingly 
recognized.  
The  accumulation  of  misfolded  proteins  in  the  cells  is  involved  in  the  pathogenesis  of  many 
neurodegenerative  diseases,  such  as  Parkinson's  disease  (PD),  Alzheimer's  disease  (AD)  and 
Huntington's disease (HD) [19,20,43]. 
Our results have demonstrated that 6-OHDA decreased the number of Notch-3 positive cells in rat 
striatum  and  substantia  nigra.  However,  mildronate  at  a  dose  of  50  mg/kg  coadministrated  with 
6-OHDA increased the number of Notch-3-positive cells close to control values.  
The Notch family of receptors and ligands plays an important role in the determination of cell fate, 
vasculogenesis and organogenesis, and the activation of Notch-1, 2 and 3 receptors has multiple roles 
during CNS development, particularly during gliogenesis [45]. Furthermore, Notch-3 is a marker of 
progenitor cells and appears to couple the Notch pathway to the regulation of cell growth [46]. The 
presence of endogenous progenitor cells in the adult mammalian brain presents an attractive alternative 
to the available therapeutic options for the treatment of PD [32]. To date, we have not found any data 
showing  Notch-3  expression  in  PD  or  PD  animal  models.  The  effect  of  mildronate  on  Notch-3 
expression is difficult to explain. However, we think that it is an interesting phenomenon and suggest 
that mildronate stimulates the adult striatal progenitor cell population.  
In addition, we demonstrated that 6-OHDA increased the number of GFAP-positive astrocytes in 
striatum and SN. This finding is consistent with previous data that demonstrated an increase in the 
levels of GFAP in 6-OHDA-lesioned structures [32,46]. The administration of mildronate at a dose of 
50 mg/kg decreased the number of GFAP-positive astrocytes to a level similar to that detected in the 
control. We consider this phenomenon to be a positive effect of mildronate because it coincided with 
the normalization of TH expression, which affects cell survival. A similar normalization effect was 
observed in studies investigating the novel anti-parkinsonian agent zonisamide, which was found to 
attenuate MPTP-induced neurotoxicity in mice [47].  
There are different hypotheses concerning the mechanisms underlying reactive astrogliosis [48,49]. 
On the one hand, activated astrocytes may stimulate microglial cells, which induce dopamine cell 
sprouting via the synthesis of neurotrophic factors [50]. Therefore, astrocytes can act as stem cells 
during  adult  neurogenesis  [51].  On  the  other  hand,  sustained  inflammatory  astrogliosis  may  have 
deteriorating effects after brain injuries and in neurodegenerative and demyelinating diseases [51].  
In the present study, we also assessed the microglial marker IBA-1, which is specifically expressed 
in macrophages/microglia and is upregulated when these cells are activated [52]. We found that the 
expression of IBA-1
 was increased by two-fold in the 6-OHDA-lesioned striatum and by 2.5-fold in 
the SN in comparison to the control group. These findings are consistent with the results described in Int. J. Mol. Sci. 2010, 11                       
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the literature, which show that 6-OHDA causes neuroinflammation and microglial activation [21] by 
increasing the expression of proinflammatory cytokines [52]. Interestingly, in the 6-OHDA-lesioned 
SN, microglial activation precedes dopamine neuronal loss [21,22]. Microglial activation is important 
because  reactive  microglia  may  have  a  destructive  influence  on  neurons.  Conversely,  activated 
microglia may stimulate the production of substances with neurotrophic properties [50]. In the present 
study, mildronate did not affect the level of IBA-1
 in the 6-OHDA-lesioned striatum, but in the SN, it 
showed a tendency to decrease the expression of IBA-1. Because IBA-1 activation coincided with an 
increase in TH and Notch-3 expression in the presence of mildronate, microglial activation may have a 
beneficial role in cell survival. 
Finally,  in  the  6-OHDA-lesioned  striatum  and  SN,  we  detected  a  considerable  increase  in  the 
expression of the inflammatory marker iNOS, which indicated a manifestation of neuroinflammatory 
processes. Similarly, iNOS overexpression has been previously observed in the 6-OHDA model [53], 
which indicates that iNOS induction plays an important role in the initial phase of neurodegeneration. 
The administration of mildronate at a dose of 50 mg/kg decreased the expression of iNOS in the SN by 
approximately two-fold, which indicates that mildronate possesses anti-inflammatory activity. 
In summary, our data suggest that mildronate is capable of regulating many endogenous molecules 
that are involved in cell survival processes. The most important findings in the present study include 
the complete prevention of the loss of TH in the 6-OHDA-lesioned striatum and the decreased number 
of  ubiquitin-positive  intracellular  inclusions.  Furthermore,  mildronate  decreased  GFAP  and  iNOS 
expression but stimulated Notch-3 expression. These data indicate that mildronate controls an array of 
cell proteins that participate in multi-faceted homeostatic mechanisms and provide neuroprotection in PD.  
4. Experimental Section 
4.1. Materials and Methods 
Animals.  Male  Wistar  rats  were  obtained  from  the  Laboratory  of  Experimental  Animals,  Riga 
Stradins  University,  Riga,  Latvia.  Each  animal  weighed  230–250  g  at  the  beginning  of  each 
experiment. All of the experimental procedures were performed in accordance with the guidelines of 
Directive  86/609/EEC  “European  Convention  for  the  Protection  of  Vertebrate  Animals  Used  for 
Experimental  and  Other  Scientific  Purposes”  (1986)  and  were  approved  by  the  Animal  Ethics 
Committee of the Food and Veterinary Service (Riga, Latvia).  
Drugs. Mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate] was obtained from the 
Joint  Stock  Company  ’’Grindex’’  (Riga,  Latvia),  dissolved  in  saline  and  prepared  as  a  2%  stock 
solution.  The  6-hydroxydopamine  (6-OHDA)  was  obtained  from  Sigma-Aldrich  (St.  Louis,  MO, 
USA), dissolved in 0.2% ascorbic acid solution and prepared as a stock solution at 20 µg/3 µL. This 
solution was made fresh and protected from light exposure. Apomorphine from Sigma-Aldrich (St. 
Louis, MO, USA) was dissolved in 0.1% ascorbic acid solution. Ketamine, xylazine and imipramine 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
The  following  antibodies  were  used:  rabbit  polyclonal  IBA-1  (Wako  Chemicals,  USA);  rabbit 
polyclonal TH (Millipore, USA); rabbit polyclonal Notch-3 (Santa Cruz Biotechnology, USA); rabbit Int. J. Mol. Sci. 2010, 11                       
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polyclonal ubiquitin (Santa Cruz Biotechnology, USA); rabbit polyclonal GFAP (DAKO, Denmark); 
and rabbit polyclonal iNOS (Abcam, UK). 
The  EnVision  detection  kit,  peroxidase-conjugated  polyclonal  goat  anti-rabbit  IgG  and  
3,3-diaminobenzidine (DAB) were purchased from DAKO, Denmark.  
4.2. Experimental Design 
The rats were adapted to the experimental conditions and divided into six groups (eight animals per 
group). Mildronate or saline (control) in a volume of 1 mL/kg was administered intraperitoneally (i.p.) 
every  day  for  14  days  at  doses  of  50  or  100  mg/kg.  On  day  15,  the  neurotoxin  6-OHDA  was 
administered  into  the  right  corpus  striatum  at  a  concentration  of  20  µg/3  µL.  The  control  group 
received artificial cerebrospinal fluid (aCSF). 
Groups: 
Group 1: Saline (i.p.) for two weeks followed by aCSF (intrastriatal)(corpus striatum). 
Group 2: Mildronate, 50 mg/kg i.p. for two weeks followed by aCSF (intrastriatal).  
Group 3: Mildronate, 100 mg/kg i.p. for two weeks followed by aCSF (intrastriatal). 
Group 4: Saline i.p. for two weeks followed by 6-OHDA (intrastriatal). 
Group 5: Mildronate, 50 mg/kg i.p. for two weeks followed by 6-OHDA (intrastriatal).  
Group 6: Mildronate, 100 mg/kg i.p. for two weeks followed by 6-OHDA (intrastriatal).  
4.3. Surgical Procedures 
After  the  intraperitoneal  administration  of  mildronate  or  saline  for  two  weeks,  the  rats  were 
anesthetized (ketamine 75 mg/kg + xylazine 10 mg/kg) and placed in a stereotaxic frame (Stoelting 
Inc., USA). Thirty minutes before the induction of general anesthesia, the rats received imipramine  
(at a dose of 20 mg/kg) to protect adrenergic neurons against the development of 6-OHDA-induced 
lesions.  
Anesthetized rats received 20 µg/3 µL 6-OHDA solution or aCSF in the right striatum using a 
Stoelting microinjector. The injection rate was 1 µL /min, and the cannula was maintained in the 
delivery position for an additional 3 min prior to its slow retraction. Coordinates (according to Paxinos 
& Watson): AP + 1.2; LM + 2.5;
 DV − 5.0 mm from the bregma.  
4.4. Rotational Behavior  
On days 14, 21 and 28 after surgery and the administration of 6-OHDA, 0.2 mg/kg apomorphine 
(dopamine  receptor  agonist)  was  injected  subcutaneously,  and  the  number  of  asymmetric 
(contralateral) rotations for each animal was monitored over 30 min. 
4.5. Brain Tissue Processing 
After  termination  of  the  rotational  behavior  test  (on  day  28),  the  rats  were  anesthetized  with 
ketamine  (150  mg/kg)  and  perfused  through  the  ascending  aorta  with  50  mL  of  isotonic  saline Int. J. Mol. Sci. 2010, 11                       
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followed by 250 mL of 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brains were 
removed and fixed at −80 ° C. 
The brain tissue was cut into 10-µm -thick sections using a cryostat at −20 ° C (Leica CM1850, Leica 
Microsystems, Germany), and 24 sections each from the corpus striatum (striatum) and substantia 
nigra (s. nigra) were obtained.  
The sections were transferred to polylysine-coated slides (3 sections on each slide). The slides were 
air-dried for 15 minutes and then immersed in ice-cold acetone for 15 min and air-dried for 2 hours. 
The slides were wrapped in aluminum foil and stored at −20 ° C. 
4.6. Immunohistochemical Examination of the Brain Tissue  
Ten-micron-thick  tissue  sections  were  stained  to  visualize  the  cells  that  were  positive  for  TH, 
ubiquitin,  Notch-3,  IBA-1,  GFAP  and  iNOS,  according  to  a  previously  described 
immunohistochemical procedure [40].  
Briefly, endogenous  peroxidase activity  was  blocked with 3.0%  H2O2  for 10 min. Nonspecific
 
primary antibody binding was blocked by incubating the slides with normal horse serum. These slides 
were incubated with rabbit polyclonal IBA-1 (Wako Chemicals, dilution at 1:500), rabbit polyclonal 
TH (Millipore, 1:400), or Notch-3 (Santa Cruz Biotechnology, 1:100), ubiquitin (1:100), or iNOS 
(Abcam, 1:100) overnight at 4 C. The slides were incubated with rabbit polyclonal GFAP (DAKO, 
1:500) for one hour at room temperature. 
The rabbit polyclonal ubiquitin antibody was obtained from Santa Cruz Biotechnology (sc9133, 
clone FL-76). The epitope of the ubiquitin antibody corresponded to amino acids 1-76 and represented 
a full-length ubiquitin molecule of human origin. This antibody labels human, mouse and rat ubiquitin 
and polyubiquitin.  
For TH, GFAP and iNOS immunostaining, the detection of bound antibody was performed using 
EnVision reagent (Dako, Denmark). To detect the expression of Notch-3, IBA-1 and ubiquitin, the 
slides were incubated with peroxidase-conjugated polyclonal goat anti-rabbit IgG for one hour. 
The  immunoperoxidase  colour  reaction  was  developed  by  incubating  the  slides  with 
diaminobenzidine  (5  min).  A  negative  control  without  primary  antibody  was  included  in  
each experiment.  
4.7. Imaging and Quantitation of Fibers and Cells  
Quantitation of cells in the striatum. Tyrosine hydroxylase-immunopositive fibers were counted 
bilaterally in six independent sections each from all of the experimental groups. The total number of 
TH-positive nerve fibers in the striatum was quantified using a × 40 objective. The region of interest 
was captured using a Motic digital camera (Motic, China) mounted on a microscope (Motic BA400) 
using Motic Image Advanced 3.2 software. Whole striatal sections were captured and analyzed. The 
results are expressed as fibers per square millimeter.  
A similar approach was utilized to count the number of GFAP, iNOS and IBA-1-positive cells. In 
addition, the number of cells that contained ubiquitin-positive inclusions was determined.  
Quantitation  of  cells  in  the  substantia  nigra.  To  quantify  the  number  of  tyrosine  hydroxylase  
(TH)-positive neurons, the positive cells were counted using a Motic BA400 microscope connected to Int. J. Mol. Sci. 2010, 11                       
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a camera at a magnification of × 40. TH-positive neurons were counted in both the ipsilateral and 
contralateral hemispheres of the brain in each of the stereotaxic regions of the SN and adjacent ventral 
tegmental area (VTA) area to ensure complete sampling of the entire structure. The stereotaxic region 
in each section was determined by examining the shape and distribution of TH-positive neurons at a 
low magnification (4× ). The substantia nigra (SN) was delineated from the VTA by reference to the 
specific anatomical landmark of the third cranial nerve rootlet. To minimize bias, all of the operators 
were assessed for counting consistency at each stereotaxic level of the SN prior to performing the cell 
counting. Intact cells with a nucleus, clear cytoplasm and axonal processes were included in the cell 
counts, and cells that appeared deformed and that lacked clear axonal processes were excluded from 
the cell counts. For each animal, six consecutive sections were counted at each stereotaxic level, and 
the  results  were  pooled  to  obtain  a  total  mean  cell  count  for  the  ipsilateral  and  contralateral 
hemispheres in each group. To ensure an unbiased cell count, all of the operators were blinded to the 
analyzed group.  
A similar approach was utilized to count the numbers of GFAP, iNOS and IBA-1-positive cells. In 
addition, the number of cells that contained ubiquitin-positive inclusions was counted.  
4.8. Statistics 
For the statistical analysis, GraphPad Prism 5 software was used. The results are expressed as the 
mean ±  SEM, and the level of significance was p < 0.05 (unpaired t-test). 
5. Conclusions 
Mildronate, a small molecule of the aza-butyrobetaine class, shows neuroprotective activity in a rat 
model  of  Parkinson's  disease  by  preventing  the  alterations  of  the  neuronal-glial  pathways  in  the  
6-OHDA-lesioned striatum and substantia nigra. We suggest that mildronate has a neuroprotective 
effect and recommend its use during the early stages of PD to delay or halt the progression of this 
neurodegenerative disease. 
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